Fig. 1From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studySELECT TRILOGY study design. The dosing regimen for study drug (ie, placebo or daclizumab) was subcutaneous (SC) every 4 weeks in all three studies of the SELECT TRILOGY [3, 4]. *Gold et al. [3]. †Giovannoni et al. [4]Back to article page